Skip to content

EBITDA margin at other companies

3M logo
3MMMM
24.5%-0.6pp
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
-35,299.7%-38,670pp
Biogen logo
BiogenBIIB
27%+0.1pp
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
48.2%+28.1pp
DuPont de Nemours, Inc. logo
DuPont de Nemours, Inc.DD
23.3%+1.5pp
Chemours logo
ChemoursCC
5.2%-5.4pp

Other financials

Income statement

See full
Revenue$200.5M+5.2%
Gross profit$64.6M+13.3%
Operating income$10.7M+3,667%
Net income$4.5M+421%
EPS (diluted)$0.25+413%

Balance sheet

See full
Cash & equivalents$195.8M+11.5%
Total debt$29.8M-10.5%
Total equity$1.2B-6.1%
Total assets$1.4B-5.6%

Cash flow

See full
Operating cash flow$5.8M-50.4%
CapEx$4.7M-51.0%
Free cash flow$1.1M-47.6%

Valuation

See full
Market cap$2.84B+53.1%
Enterprise value$2.67B+57.7%
P/S3.5×+1.2×

Profitability

See full
Gross margin32.2%-0.7pp
Operating margin8.1%-6.7pp
Net margin-7.4%-9.5pp
FCF margin8.5%+1.8pp

Returns & leverage

See full
Return on equity-4.9%-6.3pp
Debt / equity0.0×
Current ratio+0.1×

Where this comes from

Calculated from Rogers Corporation’s reported figures.

Based on trailing twelve months.

The official record: Rogers Corporation’s 10-Q, filed October 30, 2025, on SEC EDGAR. View the filing →

Ask your AI about Rogers Corporation's ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rogers Corporation's EBITDA margin?
Rogers Corporation (ROG) reported EBITDA margin of 0.1% in Q3 2025.
How has Rogers Corporation's EBITDA margin changed year-over-year?
Rogers Corporation's EBITDA margin decreased by 99.4% year-over-year, from 13.7% to 0.1%.
What is the long-term trend for Rogers Corporation's EBITDA margin?
Over 4 years (2020 to 2024), Rogers Corporation's EBITDA margin has grown at a -11.8% compound annual growth rate (CAGR), from 17.3% to 10.5%.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.